cDNA array reveals increased expression of glucose-dependent insulinotropic polypeptide following chronic clozapine treatment: role in atypical antipsychotic drug-induced adverse metabolic effects
- 13 December 2005
- journal article
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 6 (2) , 131-140
Abstract
Clozapine is an atypical antipsychotic drug with unique pharmacological and therapeutic properties. Unlike the typical antipsychotic drug, haloperidol, clozapine does not cause extrapyramidal side effects; however, weight gain, dyslipidemia, and type II diabetes are commonly associated with the use of this drug in subjects with schizophrenia. The aim of this study was to profile gene expression in the rat striatum following clozapine treatment. Chronic treatment with clozapine revealed upregulation of several genes including the glucose-dependent insulinotropic polypeptide (GIP) gene by over 200% in the rat striatum. The cDNA array results for the GIP gene were confirmed by real-time RT-PCR as well as by radioimmunoassay. Expression of the GIP gene in the central nervous system is consistent with the results of retinal GIP gene expression as reported by other investigators. Taken together, these findings implicate the possible role of GIP as a neuromodulator in the central nervous system. GIP is an insulinotropic agent with stimulatory effects on insulin synthesis and release from the pancreas. However, changes in brain GIP levels are most likely unrelated to the metabolic adverse effects (dyslipidemia, type II diabetes, weight gain) associated with clozapine treatment. Therefore, we also measured GIP gene expression in the K-cell-rich regions, duodenum and jejunum (small intestine), and plasma GIP levels using radioimmunoassay following chronic treatment with clozapine. GIP mRNA levels in the small intestine and the plasma GIP at the protein level were significantly elevated in clozapine-treated subjects. Furthermore, as observed in humans, chronic clozapine treatment also caused weight gain, and increased levels of insulin, triglycerides and leptin in the plasma. These results suggest that adverse metabolic effects associated with clozapine treatment may be related to its ability to increase intestinal gene expression for GIP.Keywords
This publication has 52 references indexed in Scilit:
- The expression of GLP‐1 receptor mRNA and protein allows the effect of GLP‐1 on glucose metabolism in the human hypothalamus and brainstemJournal of Neurochemistry, 2005
- A Prospective Study of Impairment in Glucose Control Caused by Clozapine Without Changes in Insulin ResistanceAmerican Journal of Psychiatry, 2004
- Antipsychotic-Induced Type 2 Diabetes: Evidence From a Large Health Plan DatabaseJournal of Clinical Psychopharmacology, 2003
- GIF biology and fat metabolismLife Sciences, 1999
- Molecular cloning, functional expression, and signal transduction of the GIP‐receptor cloned from a human insulinomaFEBS Letters, 1995
- Molecular Pharmacology of α2-adrenoceptor SubtypesAnnals of Medicine, 1995
- Two 3',5'‐cyclic‐adenosine monophosphate response elements in the promoter region of the human gastric inhibitory polypeptide geneFEBS Letters, 1993
- Glucose Dependent Insulinotropic Polypeptide (GIP) Infused Intravenously is Insulinotropic in the Fasting State in Type 2 (Non-Insulin Dependent) Diabetes MellitusHormone and Metabolic Research, 1989
- Adrenergic modulation of gastric inhibitory polypeptide secretion in manDigestive Diseases and Sciences, 1982
- The incretin concept todayDiabetologia, 1979